WinstonWınston
Back

This stock no longer trades (delisted July 7, 2023)

Delisted / no longer publicly traded (per market data provider) Everything below is based on the last available data — treat it as historical, not a live read.

Stock

Nymox Pharmaceutical Corporation

NYMX
Biotechnology · Healthcare
Price
$0.20
-0.00 (-0.05%)
Market Cap
$18.2M
Exchange
NASDAQ Capital Market
Winston Score
–
Winston looking sleepy
No score yet — nothing to grade.
This is a pre-revenue company — it has no sales yet, just exploration or development costs. There’s no operating business to grade on profitability, margins or cash flow, so the Winston Score stays blank until it starts booking revenue.

Share count rising — dilution

+47.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 60.5M (2018) → 89.4M (2022)

§Winston Score History

The full picture

Nymox Pharmaceutical is a small biotech company focused on developing treatments for aging-related diseases. Its lead product candidate, fexapotide triflutate (brand name NX-1207), is an injectable drug designed to treat benign prostatic hyperplasia (BPH), a common condition where the prostate gland enlarges in older men. The company also has research programs related to Alzheimer's disease diagnostics.

Nymox generates minimal revenue currently and operates primarily as a clinical-stage company, meaning it spends most of its money on research and drug development rather than selling products. It is headquartered in New Jersey and trades as a micro-cap stock. The company's potential growth depends heavily on gaining regulatory approval for fexapotide triflutate, which would offer a non-surgical alternative for BPH treatment. However, as with many small biotech firms, Nymox faces significant risks including limited cash resources, regulatory uncertainty, and the possibility that its drug candidates may not reach the market.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-128.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$4M/ year

↓ Declining (-43% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

45.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~0 months

$132,000 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Nymox Pharmaceutical Corporation has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
N/A
—
Data not available
Profit after running costs
Operating Margin
N/A
—
Data not available
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
N/A
—
Data not available
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
N/A
—
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.29
Conservative — low debt load (0.29)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial